203 filings
Page 4 of 11
8-K
bcs27f
20 May 22
Evofem Biosciences Announces Proposed Public Offering
7:55pm
8-K
ecj417yst qo04
20 May 22
Termination of a Material Definitive Agreement
6:01am
8-K
sotm27et90m7d pb
12 May 22
Regulation FD Disclosure
8:01am
8-K
45ead
5 May 22
Evofem Biosciences Announces 1-for-15 Reverse Stock Split
9:03am
8-K
1sqcau
4 May 22
Evofem Biosciences Reports First Quarter 2022
4:05pm
8-K
upyubjl6arfpbyxk5
7 Apr 22
Continued Listing Subject to Receipt of Shareholder Approval for the Reverse Stock Split of
6:51am
8-K
930xox
6 Apr 22
Entry into a Material Definitive Agreement
7:36pm
8-K
hxel4k2jmp g43q
24 Mar 22
Entry into a Material Definitive Agreement
4:03pm
8-K
mr0uovfklorjayjuw
21 Mar 22
Entry into a Material Definitive Agreement
4:35pm
8-K
rf9fxjs9 z7rss7km1y
3 Mar 22
Evofem Biosciences Reports Fourth Quarter and Year-End 2021
4:11pm
8-K
qhr7mjgn7 a5d
1 Mar 22
Entry into a Material Definitive Agreement
10:53am
8-K
5q0u 9joz2gt6m90k
28 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K/A
n977vsl im3nuvtv2d2m
16 Feb 22
Entry into a Material Definitive Agreement
4:05pm
8-K
vt2t5v7k poc9
16 Feb 22
Entry into a Material Definitive Agreement
6:22am
8-K
l47sc4q8
15 Feb 22
Regulation FD Disclosure
4:10pm
8-K
2w29m brz80k
19 Jan 22
Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021
9:01am
8-K
3urla q8b1o5v
13 Jan 22
Entry into a Material Definitive Agreement
8:43am
8-K
0z5 uizce9wzlfkn
15 Dec 21
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
qeq1lqj
9 Dec 21
Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021
8:00am
8-K
1g0fgl
8 Dec 21
Other Events
6:30am